DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Fanconi anemia complementation group U — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFanconi anemia complementation group U maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fanconi anemia complementation group u is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
X-ray repair cross complementing 2 (XRCC2) — XRCC2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8FAZ · 2.3 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Fanconi anemia is a rare autosomal recessive disease characterised by multiple congenital abnormalities, bone marrow failure, and cancer susceptibility. The mean age of onset of anaemia is 8 years, and the mean survival is 16 years; death usually results from complications of bone marrow failure. The disease is caused by biallelic inactivating mutations in more than 20 genes, and the molecular mechanism underlying bone marrow failure has remained elusive for a long time and is still a matter of debate.
Hematopoietic cell transplantation remains the only curative modality for haematological manifestations in Fanconi anemia patients. The doses of alkylating agents used in conditioning before transplantation are usually significantly decreased because of the genomic instability of Fanconi anemia cells. In one report, three Fanconi anemia patients with renal impairment were successfully transplanted using an ultra-modified regimen with ultra-reduced doses of cyclophosphamide and fludarabine.
Current treatment methods rely on anaemia correction through stem cell transplantation, but it has become more and more evident that modern and more efficient therapies need to be developed. The connection between Fanconi anemia and the development of several malignancies, especially breast, skin and blood-related cancers as well as squamous cell carcinomas, is a major concern for patients and caregivers.
No drug repurposing data specific to Fanconi anemia complementation group U were found in the provided abstracts. What is still missing is any trial design or patient stratification that distinguishes complementation group U from other Fanconi anemia subtypes, and the funding needed to test whether any existing drug could alter the course of bone marrow failure or cancer predisposition in this specific group.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Investigation · 2012 · 287 citations · open access
Molecular pathogenesis and clinical management of Fanconi anemia
AbstractFanconi anemia (FA) is a rare genetic disorder associated with a high frequency of hematological abnormalities and congenital anomalies. Based on multilateral efforts from basic scientists and clinicians, significant advances in our knowledge of FA have been made in recent years. Here we review the clinical features, the diagnostic criteria, and the current and future therapies of FA and describe the current understanding of the molecular basis of the disease.
Current Opinion in Hematology · 1999 · 33 citations
The molecular and cellular biology of Fanconi anemia
AbstractFanconi anemia is a rare autosomal recessive disease characterized by multiple congenital abnormalities, bone marrow failure, and cancer susceptibility. The mean age of onset of anemia is 8 years, and the mean survival is 16 years. Death usually results from complications of bone marrow failure. Considerable progress in Fanconi anemia research has resulted from the recent identification and cloning of three Fanconi anemia genes. The current review describes the structure and function of the Fanconi anemia genes and describes the role of the encoded Fanconi anemia proteins in a cellular pathway controlling chromosome stability.
TGF-β: a master regulator of the bone marrow failure puzzle in Fanconi anemia
AbstractFanconi anemia (FA) is a genetic disease mainly characterized by progressive bone marrow failure (BMF), congenital abnormalities, and increased predisposition to cancer (1,2). Although most patients with FA develop BMF generally during childhood, the molecular mechanism underlying BMF has remained elusive for a long time and is still a matter of debate.
Successful hematopoietic cell transplantation in Fanconi anemia patients with renal impairment using ultra‐reduced doses of cyclophosphamide and fludarabine
AbstractHematopoietic cell transplantation (HCT) remains until now the only curative modality for hematological manifestations in patients with Fanconi anemia (FA). The doses of alkylating agents used in the conditioning of this patient population before HCT are usually significantly decreased due to the genomic instability of the FA cells. FA patients with renal impairment represent a dilemma because of the need to further modify the conditioning regimen according to the degree of renal impairment to avoid additional toxicity. At our institution, we successfully transplanted three FA patients using an ultra-modified regimen.
Zenodo (CERN European Organization for Nuclear Research) · 2023 · 0 citations · open access
Current and Novel Directions in Fanconi Anemia Treatment Methods - a Literature Review
AbstractFanconi anemia is a genetically-transmitted disease caused by biallelic inactivating mutations in more than 20 genes. While its main symptoms include severe anemia, other cytopenias and skin pigmentation impairments, the aspect which concerns both patients and caregivers is the connection between Fanconi anemia and the development of several malignancies, especially breast, skin and blood-related cancers, as well as squamous cell carcinomas. Current treatment methods rely on anemia correction through stem cell transplantation, however it has become more and more evident that modern and more efficient therapies need to be developed. This needs-led literature review provides an overview of the main highlights in Fanconi anemia current and emerging therapeutic directions in order to improve the patients’ quality of life.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
